Pharmaceutical Investing VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
Pharmaceutical Investing Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results
Pharmaceutical Investing Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes
Pharmaceutical Investing BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
Pharmaceutical Investing BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
Strongbridge Biopharma Announces Acquisition of the U.S. and Canadian Rights to MACRILENâ„¢ (macimorelin) from Aeterna Zentaris
Skyharbour Partner Company Terra Clean Energy Completes Winter Drill Program with Encouraging Results and Prepares a Significant Summer Drill Program at the South Falcon East Uranium Project
Riverside Resources Moves Ahead on Plan to Spin Out Blue Jay to Shareholders After Approval at the Annual and Special Meeting